LY900014 + Insulin Lispro
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1 Diabetes Mellitus
Conditions
Type1 Diabetes Mellitus
Trial Timeline
Feb 18, 2019 → Oct 7, 2019
NCT ID
NCT03760640About LY900014 + Insulin Lispro
LY900014 + Insulin Lispro is a phase 2 stage product being developed by Eli Lilly for Type1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03760640. Target conditions include Type1 Diabetes Mellitus.
What happened to similar drugs?
1 of 2 similar drugs in Type1 Diabetes Mellitus were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04276207 | Phase 1 | Completed |
| NCT04049123 | Phase 1 | Completed |
| NCT03760640 | Phase 2 | Completed |
| NCT03465878 | Phase 1 | Completed |
| NCT03433677 | Phase 3 | Completed |
| NCT03407118 | Phase 1 | Completed |
| NCT03341299 | Phase 1 | Completed |
| NCT03341312 | Phase 1 | Completed |
| NCT03286751 | Phase 1 | Completed |
| NCT03305822 | Phase 1 | Completed |
| NCT03166124 | Phase 1 | Completed |
| NCT02942654 | Phase 1 | Completed |
| NCT02703337 | Phase 1 | Completed |
| NCT02703324 | Phase 1 | Completed |
| NCT02703350 | Phase 1 | Completed |
| NCT02317575 | Phase 1 | Completed |
Competing Products
11 competing products in Type1 Diabetes Mellitus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose | Precigen | Phase 1/2 | 26 |
| Insulin Lispro | Eli Lilly | Phase 1 | 29 |
| Selumetinib | AstraZeneca | Pre-clinical | 26 |
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 29 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 42 |
| Aspart | Novo Nordisk | Approved | 43 |
| Insulin glargine new formulation HOE901 | Sanofi | Phase 1 | 29 |
| Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin | Sanofi | Phase 1 | 29 |
| verapamil 120mg tablet + placebo | Dexcom | Phase 3 | 37 |
| UP421 | Sana Biotechnology | Phase 1 | 30 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 23 |